Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
(NQ:
)
N/A
UNCHANGED
Last Price
/ Updated:
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Press releases about
Venaxis, Inc. Announces Full Exercise of Underwriter's Over-Allotment Option
December 12, 2012
from
PR Newswire
AspenBio Pharma Changes Company Name to Venaxis, Inc.
December 12, 2012
Company Provides Update Following Special Meeting of Shareholders
Read More
from
PR Newswire
AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
November 20, 2012
from
PR Newswire
Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012
November 19, 2012
Five Star Equities Provides Stock Research on AspenBio Pharma and Cadence Pharmaceuticals
Read More
from
Marketwired News Releases
Free Research Reports on APPY, NTAP, VELT and WMT Issued by the Bedford Report
November 16, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit
Read More
from
Marketwired News Releases
AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock
November 14, 2012
from
PR Newswire
AspenBio Pharma Announces Proposed Public Offering
November 14, 2012
from
PR Newswire
AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference
November 13, 2012
from
PR Newswire
AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial
November 13, 2012
Company Remains on Track to Obtain CE Mark and Enroll First U.S. Patients Before Year End
Read More
from
PR Newswire
AspenBio Engages European-based Sales and Marketing Veteran Miquel Vernet to Consult on European Commercialization
November 06, 2012
from
PR Newswire
AspenBio Pharma to Provide Third Quarter 2012 Business Update
November 05, 2012
Conference Call and Webcast scheduled for November 13, 2012, 4:30 p.m. ET
Read More
from
PR Newswire
FDA Considering Allowing Developers of Critical Drugs/Treatments to Conduct Smaller, Faster Clinical Trials
October 22, 2012
The Paragon Report Provides Stock Research on AspenBio Pharma and Sunesis Pharmaceuticals
Read More
from
Marketwired News Releases
AspenBio Proposes Corporate Name Change to Venaxis, Inc.
October 15, 2012
from
PR Newswire
Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures
October 04, 2012
Five Star Equities Provides Stock Research on AspenBio Pharma and Keryx Biopharmaceuticals
Read More
from
Marketwired News Releases
AspenBio Plans to Initiate Pivotal Study in Fourth Quarter
September 27, 2012
FDA Meeting Held; Advancing Toward Commercialization in U.S. and EU
Read More
from
PR Newswire
AspenBio to Provide Investors with Clinical and Business Update
September 25, 2012
Conference Call and Webcast scheduled for September 27, 2012, 8:30 a.m. ET
Read More
from
PR Newswire
AspenBio to Present at 2012 Aegis Healthcare Conference
September 20, 2012
from
PR Newswire
AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
September 18, 2012
from
PR Newswire
AspenBio to Present at Rodman & Renshaw Annual Global Investment Conference
September 04, 2012
from
PR Newswire
AspenBio Pharma Focuses Resources on Development of AppyScore™ Clinical Diagnostic Test
August 15, 2012
To Provide Business Update Conference Call and Webcast Today at 5:00 p.m. ET
Read More
from
PR Newswire
AspenBio Pharma to Provide Shareholders with Business Update
August 08, 2012
Conference Call and Webcast scheduled for August 15, 2012, 5:00 p.m. ET
Read More
from
PR Newswire
AspenBio Pharma Submits Pre-IDE Information Package to FDA for AppyScore™ Appendicitis Test System
August 07, 2012
Company scheduled to meet FDA and receive feedback prior to end of third quarter
Read More
from
PR Newswire
AspenBio Pharma Enhances Product Development & Manufacturing Capabilities in Preparation for Clinical Trial and Commercialization of AppyScore™
August 01, 2012
Company engages diagnostics industry veteran, Lyndal Hesterberg, Ph.D., to spearhead production initiative
Read More
from
PR Newswire
AspenBio Pharma Executes Worldwide License Agreement for its Animal Health Assets
July 30, 2012
Global veterinary health company to advance product development
Read More
from
PR Newswire
AspenBio Pharma Engages Tiberend Strategic Advisors as Investor and Public Relations Agency of Record
July 26, 2012
from
PR Newswire
AspenBio Pharma Notified by NASDAQ That It Regained Compliance With All NASDAQ Capital Market Continued Listing Standards
July 10, 2012
from
Marketwired News Releases
AspenBio Pharma Announces Closing of Public Offering of 6,100,000 Shares of Common Stock
June 25, 2012
from
Marketwired News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here